secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0000950170-23-072612
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma adopts Sixth Amended and Restated Bylaws effective December 18, 2023
-------------------------------------------------------------------------------

- Board designated at eight directors; amendments conform to revised DGCL.
- Changes include updated meeting notice rules, adjourned meetings, record date.
- Board may now designate any person (not just officers) to chair stockholder meetings.
- Director removal standard aligned with DGCL and Certificate of Incorporation.
- Administrative updates: gender-neutral terms, waiver by electronic transmission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017023072612/0000950170-23-072612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017023072612/meip-20231218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-072612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer